Home Metabolism FTase

FTase

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR
Cat.No. Product Name Information Product Use Citations Product Validations
S7465 FTI 277 HCl FTI 277 HCl is a potent and selective farnesyltransferase (FTase) inhibitor with IC50 of 500 pM, about 100-fold selectivity over the closely related GGTase I. This compound inhibits cell growth and induces apoptosis. This chemical is effective in clearing HDV viremia.
Molecular Biology of the Cell, March 1, 2019, 607-621
EMBO J, 2025, 44(4):1185-1219
BMC Biol, 2025, 23(1):233
Verified customer review of FTI 277 HCl
S1453 Tipifarnib (IND 58359) Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. Phase 3.
Sci Rep, 2025, 15(1):6832
PLoS One, 2025, 20(9):e0331440
Cell Rep, 2023, 42(9):113098
Verified customer review of Tipifarnib (IND 58359)
S2797 Lonafarnib (SCH66336) Lonafarnib (SCH66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM in cell-free assays, respectively. Phase 3.
PLoS Pathog, 2025, 21(10):e1013558
iScience, 2025, 28(2):111864
Sci Rep, 2025, 15(1):34331
Verified customer review of Lonafarnib (SCH66336)
S7467 LB42708 LB42708 is an orally active farnesyltransferase (FTase) inhibitor with IC50 of 0.8, 1.2, and 2.0 nM toward H-ras, N-ras, and K-ras, respectively.
Cancer Research Communications, 2024, 2454-2462
Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221